Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iStopMM phase 2 treatment study for smoldering and active multiple myeloma
2017-004785-10Phase 2Active
- Sponsor
- Landspitali
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide, dexamethasone and carfilzomib in smoldering multiple myeloma (SMM) and multiple myeloma (MM) (2 arms), sponsored by Landspitali. Primary endpoint: MRD negativity. Started Nov 2018; status: active.
02
Drugs
lenalidomidedexamethasonecarfilzomib
03
Conditions
smoldering multiple myeloma (SMM)multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004785-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004785-10.